K. Sakai et al., Comparison of p53, Ki-67, and CD44v6 expression between primary and matched metastatic lesions in ovarian cancer, GYNECOL ONC, 72(3), 1999, pp. 360-366
Objective. Many studies have demonstrated that clinically evident tumor cel
ls already carry multiple genetic alterations and further accumulation of g
enetic alteration causes tumor progression which plays a role in metastasis
. Therefore, it could be expected that malignant potential in the metastati
c site is more aggressive than that in the primary site. Using several immu
nohistochemical markers (p53, Ki-67, and CD44v6), we investigated an altera
tion of malignant potential.
Methods. We immunohistochemically examined expression of p53, Ki-67, and CD
44 in primary and metastatic lesions of ovarian cancer. Fifty-six samples o
f primary lesions and matched metastatic sites from 56 patients with primar
y epithelial ovarian cancers were included in this study.
Results. In 16 cases (28%), the histological grade of the metastatic lesion
increased. This difference was statistically significant (P = 0.0232). In
16 cases (28%), the expression of p53 increased in the metastatic lesions,
in 5 pairs from negative to positive, whereas the case decrease in the meta
static lesions was only 1. This difference was statistically significant (P
= 0.0046). There was no significant difference in Ki-67 labeling indices a
nd expression of CD44v6 between the primary and matched metastatic lesions.
The degree of p53 expression in the metastatic lesions significantly corre
lated with disease-free survival (P = 0.0482), whereas that in the primary
lesions did not. Moreover, high p53 expression in the metastatic lesions si
gnificantly correlated with disease-free survival in multivariate analysis.
Conclusions. The p53 expression in metastatic lesions may reflect an aggres
sive biologic behavior in ovarian cancer. (C) 1999 Academic Press.